Brain Booster
Natural health product licensed in Canada
- Licence holder
- NorthMED Life Sciences Inc.
- NPN or DIN-HM
- 80143097
- Status
- Active licence
- Licence date
- 31 July 2025
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Sel interne de (2R)-2-(Acétyloxy)-3-carboxy-N,N,N-triméthyl-1-propanaminium Source : Dichlorhydrate d'arginate d'acétyle-L-carnitine | 50 mg | Not calculated |
| Ginkgo biloba Source : Ginkgo biloba - feuille Extract : Matériel brut sec Extraction ratio : 50:1 Dry plant equivalent : 2,500 mg Potency : 6 % Terpene lactones | 50 mg | Not calculated |
| Ginkgo biloba Source : Ginkgo biloba - feuille Potency : 24 % Flavonoid glycosides | Not specified | Not calculated |
| Bacopa monnieri Source : Bacopa monnieri - plante entière Potency : 40 % Bacosides | 150 mg | Not calculated |
| Hypericum perforatum Source : Hypericum perforatum - herb top Extract : Matériel brut sec Extraction ratio : 5:1 Dry plant equivalent : 650 mg Potency : 0.28 % Hypericin | 130 mg | Not calculated |
| Phosphatidylsérine | 10 mg | Not calculated |
| [5R-(5alpha, 9beta, 11E)]-5-amino-11-éthylidène-5 ,6,9,10-tétrahydro-7-méthyl-5 ,9-méthane-cycloocta [b] pyridine-2 (1H)-one Source : Huperzine A | 10 Microgrammes | Not calculated |
| [5R-(5alpha, 9beta, 11E)]-5-amino-11-éthylidène-5 ,6,9,10-tétrahydro-7-méthyl-5 ,9-méthane-cycloocta [b] pyridine-2 (1H)-one Source : Huperzia serrata - plante entière | 10 Microgrammes | Not calculated |
| 2-(diméthylamino)éthanol Source : Bitartrate de déanol | 50 mg | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Stéarate de magnésium, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18 years | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to enhance cognitive function and memory in adults. Helps to support peripheral circulation. Helps (to) support memory.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80143097
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.